Literature DB >> 8977317

Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface.

M Wolfram1, M Fuchs, M Wiese, Y D Stierhof, P Overath.   

Abstract

Leishmania are protozoan parasites which invade mammalian macrophages and multiply as amastigotes in phagolysosomes (parasitophorous vacuoles). Using L. mexicana and bone marrow-derived macrophages (BMM), the question is addressed whether infected BMM induced to express major histocompatibility complex class II molecules can present defined antigens to specific T helper type 1 cells. As a model antigen, a membrane-bound acid phosphatase (MAP), a minor protein associated with intracellular vesicles in amastigotes, was either overexpressed at the surface of the parasites or overexpressed in a soluble form leading to antigen secretion into the parasitophorous vacuole. Presentation of MAP epitopes by these three types of amastigotes was then compared for macrophages containing live parasites or amastigotes inactivated by drug treatment. It is shown that surface-exposed and secreted MAP can be efficiently presented to T cells by macrophages harboring live amastigotes. Therefore, the parasitophorous vacuole communicates by vesicular membrane traffic with the plasmalemma of the host cell. The intracellular MAP of wild-type cells or the abundant lysosomal cysteine proteinases are not or only inefficiently presented, respectively. After killing of the parasites, abundant proteins such as overexpressed MAP and the cysteine proteinases efficiently stimulate T cells, while wild-type MAP levels are not effective. We conclude that intracellular proteins of intact amastigotes are not available for presentation, while after parasite inactivation, presentation depends on antigen abundance and possibly stability. The cell biological and possible immunological consequences of these results are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977317     DOI: 10.1002/eji.1830261248

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Proteophosphoglycans of Leishmania mexicana. Molecular cloning and characterization of the Leishmania mexicana ppg2 gene encoding the proteophosphoglycans aPPG and pPPG2 that are secreted by amastigotes and promastigotes.

Authors:  U Göpfert; N Goehring; C Klein; T Ilg
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

2.  Proteophosphoglycan, a major secreted product of intracellular Leishmania mexicana amastigotes, is a poor B-cell antigen and does not elicit a specific conventional CD4+ T-cell response.

Authors:  T Aebischer; D Harbecke; T Ilg
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

3.  Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.

Authors:  T Aebischer; M Wolfram; S I Patzer; T Ilg; M Wiese; P Overath
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Revisiting the Principles of Designing a Vaccine.

Authors:  Shubhranshu Zutshi; Sunil Kumar; Prashant Chauhan; Bhaskar Saha
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Leishmania spp. Proteome Data Sets: A Comprehensive Resource for Vaccine Development to Target Visceral Leishmaniasis.

Authors:  Toni Aebischer
Journal:  Front Immunol       Date:  2014-06-10       Impact factor: 7.561

Review 6.  Transgenic Leishmania and the immune response to infection.

Authors:  L Beattie; K J Evans; P M Kaye; D F Smith
Journal:  Parasite Immunol       Date:  2008-02-04       Impact factor: 2.280

7.  In vivo recognition of ovalbumin expressed by transgenic Leishmania is determined by its subcellular localization.

Authors:  Sara Prickett; Peter M Gray; Sara L Colpitts; Phillip Scott; Paul M Kaye; Deborah F Smith
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.